

Dr. XXXXX
Disclosure List

Research Funding (Site Fees)

AstraZeneca, CSL Vifor, NovoNordisk, Pfizer, Rivus

Consultant

35Pharma, Abbott, Acorai, Amgen, Bayer, Bodyport, Boston Scientific, CSL Vifor, General Prognostics, Impulse Dynamics, Regeneron, Rivus, Story Health

Honoraria;

Bayer, Abbott, Impulse Dynamics, Boston Scientific, Medtronic, Edwards Life Sciences, Biotronik, General Prognostics, Story Health, Acorai

CEC (Clinical Events Committee)

Relieve Cardiovascular, Inc.

Other Research Support (Data Analytic Center Fees)

Astra Zeneca, CSL Vifor

Stock Ownership

ISHI, Pulsi

Text to be put in manuscripts

Dr. XXXXX reports research funding (site fees) from AstraZeneca, CSL Vifor, NovoNordisk, Pfizer, Rivus; consultant fees from 35Pharma, Abbott, Acorai, Amgen, Bayer, Boston Scientific, CSL Vifor, General Prognostics, Impulse Dynamics, Rivus, and Story Health; other research support (data analytic center fees) from Astra Zeneca and Vifor Pharma; and stock ownership for ISHI and Pulsi.